) -- Check out the acceleration in the number of prescriptions written for


(VVUS) - Get Report

weight-loss pill Qsymia. The uptick starts at the beginning of July when Vivus was finally able to sell Qsymia in retail pharmacies instead of by mail order only.

Vivus has also started direct-to-consumer advertising of Qsymia.

Two weeks of surging script numbers isn't enough to draw any firm conclusions about a Qsymia marketing rebound but it's definitely something to watch closely.

Meantime, the nascent launch of

Arena Pharmaceuticals'

(ARNA) - Get Report

Belviq looks underwhelming. At best, Belviq scripts are tracking in line with Qsymia's early performance (not depicted on the chart above.)

But factor in the considerable number of free Belviq samples being given out -- as much as 60% of the total scripts to date -- and Arena's weight-loss pill has a long way to go to meet even diminished expectations.

Vivus has not set a date to report second-quarter earnings report but the consensus sales estimate for Qsymia is just under $8 million.

Here's a chart of the relative stock performance of Vivus and Arena since July 1:

Image placeholder title


data by


But look what happens when

Orexigen Therapeutics


is added to the chart:

Image placeholder title


data by


Investors are definitely running up the value of Orexigen in anticipating of a positive outcome from the cardiovascular safety study of its weight-loss pill Contrave.

-- Reported by Adam Feuerstein in Boston.

Follow @AdamFeuerstein

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.